AIM ImmunoTech Inc. — Q3 2020 Form 10-Q
Reporting period: Three and nine months ended September 30, 2020. Unless stated otherwise, financial amounts below are in thousands of dollars. AIM is a development-stage immunopharma company focused on Ampligen and Alferon; Ampligen was not FDA-approved or marketed in the United States.
Financial performance
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $36 | $61 | $121 | $90 |
| Operating loss | $(3,355) | $(3,205) | $(10,002) | $(9,355) |
| Net loss | $(3,306) | $(2,948) | $(10,466) | $(8,341) |
| Loss per share, basic and diluted | $(0.08) | $(1.13) | $(0.36) | $(4.41) |
- Revenue came from Ampligen cost-recovery programs, including expanded-access and open-label treatment programs; management attributed period-to-period changes mainly to order and shipment timing.
- Nine-month costs and expenses were $10,123, including production costs of $608, R&D of $3,445, and G&A of $6,070. No conventional operating margin is meaningful given minimal revenue and continuing development costs.
- Operating cash use was $7,514 for the first nine months, versus $6,778 in 2019. Investing activities used $8,982, largely reflecting purchases of marketable securities; financing provided $53,522.
Financial position and material changes
- At September 30, cash and cash equivalents were $38,496, short-term marketable securities $1,144, and long-term marketable securities $14,836. Cash, cash equivalents, and marketable securities totaled $54,476, versus $8,778 at December 31, 2019.
- Total assets were $64,164 and stockholders’ equity was $61,112. Current assets of $39,757 substantially exceeded current liabilities of $795.
- Cash rose primarily due to equity financing: financing activities included $58,066 of net proceeds from stock sales. Common shares outstanding increased from 10.4 million at year-end 2019 to 40.7 million at September 30, 2020, materially diluting existing holders.
- The company paid off the Chicago Venture Partners note in May and the Atlas Sciences note in June; the balance sheet reported no notes payable at September 30. Remaining obligations included a $2,160 sale-leaseback financing obligation, including its current portion, and operating lease liabilities.
- Q3 net loss increased 12% year over year, mainly from higher G&A, partly offset by lower R&D, production, and interest expense and a smaller warrant-revaluation gain. Nine-month net loss increased 25%, with comparisons affected by warrant revaluations, debt-extinguishment items, and a 2019 insurance settlement.
- Basic and diluted loss per share improved substantially versus 2019, while weighted-average shares rose sharply; the share-count change is central to interpreting the per-share comparison.
Outlook, developments, and risks
- No specific revenue, earnings, or cash-flow guidance was provided. Management said it would seek senior co-development partners and could reduce discretionary spending, including some R&D, if needed. It cautioned that additional financing may be required if Ampligen is not commercialized or Alferon sales do not resume.
- COVID-19 work included a Roswell Park Phase 1/2a study of Ampligen plus interferon in cancer patients with COVID-19, and a planned intranasal prophylaxis study supported by Amarex. The latter was expected to require approximately $514 for Phase I, an additional $650 for Phase II, and an estimated $4,500 in other costs. These are planned costs, not reported expenditures or proof of efficacy.
- Management cited preliminary laboratory findings, including a Utah State University report of reduced SARS-CoV-2 viral yields. Clinical benefit in people remains unproven; the filing stresses that animal and laboratory results may not predict human outcomes and that trials, regulatory approvals, funding, and manufacturing remain uncertain.
- Ampligen’s U.S. NDA for ME/CFS had received an FDA Complete Response Letter, and further studies and work may be required. Argentine commercial launch remained subject to final product inspection and release. Alferon production was on hold, with no definitive timetable to restart; FDA inspection and product-release approval would be required.
- COVID-19 could disrupt trial enrollment, sites, staffing, shipping, and regulatory review. Other material risks include dependence on external partners and financing, uncertain product approvals and commercialization, and potential manufacturing issues. The company reported a contract dispute with BioLife; the counterclaim was $96,676, and the outcome was uncertain.
- After quarter-end, AIM disclosed a five-year CEO employment agreement with $850 annual base salary, a $350 target bonus, annual options, and potential awards equal to 3% of specified licensing/acquisition proceeds. The filing also reports an October expansion of the ME/CFS expanded-access program to include certain post-COVID patients.
Important facts for investors to verify
- Whether cash and marketable securities, together with the reported operating cash use and planned trial costs, are sufficient to fund operations and development plans.
- Actual clinical-trial initiation, enrollment, results, cost, and regulatory status for COVID-19, cancer, and ME/CFS programs; distinguish preliminary research from clinical evidence.
- Progress toward Argentine Ampligen commercialization and the approvals, inspection, manufacturing, and release requirements for Alferon production.
- Share issuance, warrant exercises, remaining potential dilution, and the terms and costs of future financing or partnering arrangements.
- The basis and progress of the BioLife litigation, and the financial and governance implications of the CEO compensation agreement and contingent awards.